| Literature DB >> 33076863 |
Yuan-Yuan Lei1, Suzanne C Ho2, Carol Kwok3, Ashley Cheng3, Ka Li Cheung1, Roselle Lee1, Winnie Yeo4,5.
Abstract
BACKGROUND: To compare change in level of physical activity between pre-and post- diagnosis of breast cancer in Chinese women.Entities:
Keywords: Breast cancer; Chinese women; Exercise; Physical activity; Pre- and post-diagnosis
Mesh:
Year: 2020 PMID: 33076863 PMCID: PMC7574482 DOI: 10.1186/s12885-020-07517-6
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Fig. 1Study flow chart. Abbreviations: m, month; dx, diagnosis
Baseline socio-demographic and clinical characteristics of patients included in this study (n = 1019)
| Characteristics | Number of patients | Frequency, % |
|---|---|---|
| Age, mean ± SD, year | 52.1 ± 8.8 | |
| Education level | ||
| High school or below | 868 | 85.2 |
| Collage or above | 151 | 14.8 |
| Marital status | ||
| Married or cohabitating | 728 | 71.4 |
| Unmarried or divorced or widowed | 291 | 28.6 |
| Household income (HKD/month) | ||
| < 15,000 | 463 | 45.4 |
| 15,000-30,000 | 326 | 32.0 |
| 30,000-50,000 | 151 | 14.8 |
| ≥ 50,000 | 79 | 7.8 |
| Employment status | ||
| Full time | 378 | 37.1 |
| Part time | 129 | 12.7 |
| Not working | 512 | 50.2 |
| Menopausal status | ||
| Pre-menopausal | 539 | 52.9 |
| Post-menopausal | 480 | 47.1 |
| BMI at diagnosis, kg/m2 | ||
| Underweight (< 18.5) | 37 | 3.6 |
| Normal (18.5–22.9) | 488 | 47.9 |
| Overweight (23–24.9) | 209 | 20.5 |
| Obese (≥25) | 285 | 28.0 |
| Number of comorbidities | ||
| None | 629 | 61.7 |
| 1 | 259 | 25.4 |
| 2 | 101 | 9.9 |
| ≥ 3 | 30 | 2.9 |
| AJCC stage at diagnosis | ||
| 0-I | 375 | 36.9 |
| II | 471 | 46.2 |
| III | 169 | 16.6 |
| Missing | 4 | 0.4 |
| Histology | ||
| IDC | 858 | 84.2 |
| ILC | 31 | 3.0 |
| DCIS | 56 | 5.5 |
| Others | 74 | 7.3 |
| ER status | ||
| Positive | 763 | 74.9 |
| Negative | 233 | 22.9 |
| Missing | 23 | 2.3 |
| PR status | ||
| Positive | 598 | 58.7 |
| Negative | 395 | 38.8 |
| Missing | 26 | 2.6 |
| HER 2 status | ||
| Positive | 274 | 26.9 |
| Negative | 686 | 67.3 |
| Missing | 59 | 5.8 |
| Surgery | ||
| Mastectomy | 628 | 61.6 |
| Conservation | 391 | 38.4 |
| Chemotherapy | ||
| Yes | 774 | 76.0 |
| No | 245 | 24.0 |
| Radiotherapy | ||
| Yes | 721 | 70.8 |
| No | 298 | 29.2 |
| Endocrine therapy | ||
| Yes | 777 | 76.3 |
| No | 242 | 23.7 |
| Smoking status | ||
| Yes | 11 | 1.1 |
| No | 1008 | 98.9 |
| Drinking status | ||
| Yes | 15 | 1.5 |
| No | 1004 | 98.5 |
Abbreviations: SD standard deviation, HKD Hong Kong dollars, BMI body mass index, AJCC American joint Committee on cancer, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, DCIS ductal carcinoma in situ, ER estrogen receptor, PR progesterone receptor, HER 2 human epidermal-growth-factor receptor 2
Comparison of level of physical activity across four study time-points
| Level of recreational physical activity | T0 | T1 | T2 | T3 | Mean of T1,2,3 | |
|---|---|---|---|---|---|---|
| MET-hours/week, mean ± SD | 5.9 ± 11.2 | 9.9 ± 13.0 | 9.8 ± 14.2 | 9.3 ± 14.4 | 9.6 ± 11.6 | < 0.001 |
| Physical activity group, n (%) | ||||||
| No exercise | 473 (46.4) | 209 (20.5) | 298 (29.2) | 340 (33.4) | 111 (10.9) | |
| Low-exercise-level group | 335 (32.9) | 465 (45.6) | 397 (39.0) | 376 (36.9) | 550 (54.0) | |
| High-exercise-level group | 211 (20.7) | 345 (33.9) | 324 (31.8) | 303 (29.7) | 358 (35.1) | |
Abbreviations: MET metabolic equivalent of task, SD standard deviation
Changes from no or low to high level of exercise group for individual patient by baseline socio-demographic and clinical factors
| Characteristics | N | % | Changes from no or low to high exercise group, n (%) | |
|---|---|---|---|---|
| Total | 1019 | 100.0 | 211 (20.7) | |
| Age at diagnosis, year | 0.068 | |||
| < 40 | 92 | 9.0 | 13 (14.1) | |
| 40–49 | 329 | 32.3 | 78 (23.7) | |
| 50–59 | 394 | 38.7 | 87 (22.1) | |
| ≥ 60 | 204 | 20.0 | 33 (16.3) | |
| Education | 0.954 | |||
| High school or below | 868 | 85.2 | 161 (20.7) | |
| Collage or above | 151 | 14.8 | 50 (20.5) | |
| Marital status | 0.079 | |||
| Married or cohabitating | 728 | 71.4 | 2.7 (22.1) | |
| Unmarried or divorced or widowed | 291 | 28.6 | 1.3 (17.2) | |
| Household income, HKD/month | 0.177 | |||
| < 15,000 | 463 | 45.4 | 92 (29.9) | |
| 15,000-30,000 | 326 | 32.0 | 64 (19.6) | |
| 30,000-50,000 | 151 | 14.8 | 31 (20.5) | |
| ≥ 50,000 | 79 | 7.8 | 24 (30.4) | |
| Employment status | 0.472 | |||
| Full time | 378 | 37.1 | 77 (20.4) | |
| Part time | 129 | 12.7 | 22 (17.1) | |
| Not working | 512 | 50.2 | 112 (21.9) | |
| Menopausal status | 0.055 | |||
| Premenopausal | 539 | 52.9 | 124 (23.0) | |
| Postmenopausal | 480 | 47.1 | 87 (18.1) | |
| BMI at diagnosis, kg/m2 | 0.007 | |||
| Underweight (< 18.5) | 37 | 3.6 | 9 (24.3) | |
| Normal (18.5–22.9) | 488 | 47.9 | 108 (22.1) | |
| Overweight (23–24.9) | 209 | 20.5 | 54 (25.8) | |
| Obese (≥25) | 285 | 28.0 | 40 (14.0) | |
| Number of comorbidities | 0.163 | |||
| None | 629 | 61.7 | 144 (22.9) | |
| 1 | 259 | 25.4 | 46 (17.8) | |
| 2 | 101 | 9.9 | 17 (16.8) | |
| ≥ 3 | 30 | 2.9 | 4 (13.3) | |
| AJCC stage at diagnosis | 0.024 a | |||
| 0-I | 375 | 36.9 | 61 (16.2) | |
| II | 471 | 46.2 | 109 (23.1) | |
| III | 169 | 16.6 | 41 (24.3) | |
| Missing | 4 | 0.4 | 0 (0) | |
| Histology | 0.899 | |||
| IDC | 858 | 84.2 | 176 (20.5) | |
| ILC | 31 | 3.0 | 8 (25.8) | |
| DCIS | 56 | 5.5 | 11 (19.6) | |
| Others | 74 | 7.3 | 16 (21.6) | |
| ER status | 0.969 a | |||
| Positive | 763 | 74.9 | 47 (20.2) | |
| Negative | 233 | 22.9 | 159 (20.8) | |
| Missing | 23 | 2.3 | 5 (21.7) | |
| PR status | 0.952 a | |||
| Positive | 598 | 58.7 | 81 (20.5) | |
| Negative | 395 | 38.8 | 124 (20.7) | |
| Missing | 26 | 2.6 | 6 (23.1) | |
| HER 2 status | 0.832 a | |||
| Positive | 274 | 26.9 | 146 (20.1) | |
| Negative | 686 | 67.3 | 55 (21.3) | |
| Missing | 59 | 5.8 | 10 (16.9) | |
| Surgery | 0.521 | |||
| Mastectomy | 628 | 61.6 | 126 (20.1) | |
| Conservation | 391 | 38.4 | 85 (21.7) | |
| Chemotherapy | 0.034 | |||
| Yes | 774 | 76.0 | 172 (22.2) | |
| No | 245 | 24.0 | 39 (15.9) | |
| Radiotherapy | 0.424 | |||
| Yes | 721 | 70.8 | 154 (21.4) | |
| No | 298 | 29.2 | 57 (19.1) | |
| Endocrine therapy | 0.480 | |||
| Yes | 777 | 76.3 | 157 (20.2) | |
| No | 242 | 23.7 | 54 (22.3) | |
| Smoking status | 0.133 | |||
| Yes | 11 | 1.1 | 0 (0) | |
| No | 1008 | 98.9 | 211 (20.9) | |
| Drinking status | 1.00 | |||
| Yes | 11 | 1.1 | 3 (20.7) | |
| No | 1008 | 98.9 | 208 (20.7) | |
a Missing group did not include in P value test
Abbreviations: HKD Hong Kong dollars, BMI body mass index, AJCC American joint Committee on cancer, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, DCIS ductal carcinoma in situ, ER estrogen receptor, PR progesterone receptor, HER 2 human epidermal-growth-factor receptor 2
Absolute changes in level of physical activity between pre- and post-diagnosis by baseline socio-demographic and clinical factors
| Characteristics | N | % | Changes in MET-hours/week, | |
|---|---|---|---|---|
| Total | 1019 | 100.0 | 3.7 ± 12.1 | |
| Age at diagnosis, year | 0.011 | |||
| < 40 | 92 | 9.0 | 4.2 ± 10.8 | |
| 40–49 | 329 | 32.3 | 4.8 ± 11.2 | |
| 50–59 | 394 | 38.7 | 4.0 ± 12.5 | |
| ≥ 60 | 204 | 20.0 | 1.3 ± 13.2 | |
| Education | 0.918 | |||
| High school or below | 868 | 85.2 | 3.7 ± 12.5 | |
| Collage or above | 151 | 14.8 | 3.6 ± 9.5 | |
| Marital status | 0.006 | |||
| Married or cohabitating | 728 | 71.4 | 4.3 ± 12.6 | |
| Unmarried or divorced or widowed | 291 | 28.6 | 2.2 ± 10.8 | |
| Household income, HKD/month | 0.059 | |||
| < 15,000 | 463 | 45.4 | 3.2 ± 12.9 | |
| 15,000-30,000 | 326 | 32.0 | 4.2 ± 11.3 | |
| 30,000-50,000 | 151 | 14.8 | 2.6 ± 12.3 | |
| ≥ 50,000 | 79 | 7.8 | 6.7 ± 10.4 | |
| Employment status | < 0.001 | |||
| Full time | 378 | 37.1 | 2.3 ± 13.4 | |
| Part time | 129 | 12.7 | 1.7 ± 14.2 | |
| Not working | 512 | 50.2 | 5.2 ± 10.3 | |
| Menopausal status | 0.299 | |||
| Premenopausal | 539 | 52.9 | 4.7 ± 11.6 | |
| Postmenopausal | 480 | 47.1 | 2.6 ± 12.6 | |
| BMI at diagnosis, kg/m2 | 0.086 | |||
| Underweight (< 18.5) | 37 | 3.6 | 5.1 ± 13.5 | |
| Normal (18.5–22.9) | 488 | 47.9 | 4.1 ± 12.3 | |
| Overweight (23–24.9) | 209 | 20.5 | 4.6 ± 12.1 | |
| Obese (≥25) | 285 | 28.0 | 2.2 ± 11.6 | |
| Number of comorbidities | 0.002 | |||
| None | 629 | 61.7 | 4.8 ± 12.0 | |
| 1 | 259 | 25.4 | 2.2 ± 12.7 | |
| 2 | 101 | 9.9 | 1.2 ± 10.8 | |
| ≥ 3 | 30 | 2.9 | 1.3 ± 11.4 | |
| AJCC stage at diagnosis | 0.352 a | |||
| 0-I | 375 | 36.9 | 3.2 ± 11.7 | |
| II | 471 | 46.2 | 3.9 ± 13.1 | |
| III | 169 | 16.6 | 4.4 ± 10.3 | |
| Missing | 4 | 0.4 | −5.0 ± 10.3 | |
| Histology | 0.437 | |||
| IDC | 858 | 84.2 | 3.6 ± 12.2 | |
| ILC | 31 | 3.0 | 6.4 ± 11.4 | |
| DCIS | 56 | 5.5 | 2.3 ± 10.0 | |
| Others | 74 | 7.3 | 4.7 ± 13.3 | |
| ER status | 0.394 a | |||
| Positive | 763 | 74.9 | 3.8 ± 11.5 | |
| Negative | 233 | 22.9 | 3.6 ± 14.0 | |
| Missing | 23 | 2.3 | 0.3 ± 11.4 | |
| PR status | 0.214 a | |||
| Positive | 598 | 58.7 | 4.0 ± 11.8 | |
| Negative | 395 | 38.8 | 3.5 ± 12.6 | |
| Missing | 26 | 2.6 | −0.2 ± 11.8 | |
| HER 2 status | 0.124 a | |||
| Positive | 274 | 26.9 | 3.7 ± 12.8 | |
| Negative | 686 | 67.3 | 4.0 ± 12.1 | |
| Missing | 59 | 5.8 | 0.6 ± 9.4 | |
| Surgery | 0.648 | |||
| Mastectomy | 628 | 61.6 | 3.8 ± 13.1 | |
| Conservation | 391 | 38.4 | 3.5 ± 10.4 | |
| Chemotherapy | 0.127 | |||
| Yes | 774 | 76.0 | 4.0 ± 12.7 | |
| No | 245 | 24.0 | 2.7 ± 10.1 | |
| Radiotherapy | 0.944 | |||
| Yes | 721 | 70.8 | 3.7 ± 11.7 | |
| No | 298 | 29.2 | 3.7 ± 13.2 | |
| Endocrine therapy | 0.789 | |||
| Yes | 777 | 76.3 | 3.6 ± 11.2 | |
| No | 242 | 23.7 | 3.9 ± 14.6 | |
| Smoking status | 0.455 | |||
| Yes | 11 | 1.1 | 1.0 ± 3.7 | |
| No | 1008 | 98.9 | 3.7 ± 12.2 | |
| Drinking status | 0.866 | |||
| Yes | 15 | 1.5 | 4.2 ± 11.6 | |
| No | 1004 | 98.5 | 3.7 ± 12.1 | |
a Missing group did not include in P value test
Abbreviations: MET metabolic equivalent of task, SD standard deviation, HKD Hong Kong dollars, BMI body mass index, AJCC American joint Committee on cancer, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, DCIS ductal carcinoma in situ, ER estrogen receptor, PR progesterone receptor, HER 2 human epidermal-growth-factor receptor 2